{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Squamous+Cell+Carcinoma%2C+Not+Otherwise+Specified&page=29", "query": { "condition": "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 1556, "total_pages": 156, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Squamous+Cell+Carcinoma%2C+Not+Otherwise+Specified&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Squamous+Cell+Carcinoma%2C+Not+Otherwise+Specified&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T19:07:46.645Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00001603", "title": "The Effects of Upper Airway and Digestive Tract Tumors on the Immune System", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophageal Neoplasm", "Head and Neck Neoplasm", "Laryngeal Neoplasm", "Papilloma", "Squamous Cell Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute on Deafness and Other Communication Disorders (NIDCD)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 93, "start_date": "1996-12", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001603" }, { "nct_id": "NCT04065555", "title": "Intratumoral Microdosing of TAK-981 in Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "TAK-981", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "BIOLOGICAL" }, { "name": "TAK-981 + Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "TAK-981 + Avelumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "Presage Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-10-07", "completion_date": "2022-07-20", "has_results": false, "last_update_posted_date": "2022-07-29", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 6, "location_summary": "Ann Arbor, Michigan • New York, New York • North New Hyde Park, New York + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "North New Hyde Park", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04065555" }, { "nct_id": "NCT01015664", "title": "Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Tennessee Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-12-17", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01015664" }, { "nct_id": "NCT00006106", "title": "ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lip and Oral Cavity Cancer", "Head and Neck Cancer", "Oropharyngeal Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "ONYX-015", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 0, "start_date": "1999-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006106" }, { "nct_id": "NCT04675333", "title": "Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "evorpacept", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin; 5FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ALX Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2021-05-10", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 13, "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 10 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04675333" }, { "nct_id": "NCT04242199", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "MSI-H/dMMR Tumors", "Cutaneous Squamous Cell Carcinoma", "Urothelial Carcinoma", "Cervical Cancer", "HepatoCellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Small-cell Lung Cancer", "Mesothelioma", "PD-L1 Amplified Tumor (9p24.1)", "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "INCB099280", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2020-09-04", "completion_date": "2024-11-21", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04242199" }, { "nct_id": "NCT06914999", "title": "Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Head and Neck Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Oropharyngeal Squamous Cell Carcinoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Intensity-Modulated Proton Therapy", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sodium Fluoride F-18", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-12-03", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06914999" }, { "nct_id": "NCT04574635", "title": "Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Infiltrating Cervical Carcinoma", "Metastatic Cervical Carcinoma", "Recurrent Cervical Carcinoma", "Stage I Cervical Cancer FIGO 2018", "Stage IA Cervical Cancer FIGO 2018", "Stage IA1 Cervical Cancer FIGO 2018", "Stage IA2 Cervical Cancer FIGO 2018", "Stage IB Cervical Cancer FIGO 2018", "Stage IB1 Cervical Cancer AJCC v8", "Stage IB2 Cervical Cancer FIGO 2018", "Stage IB3 Cervical Cancer FIGO 2018", "Stage II Cervical Cancer FIGO 2018", "Stage IIA Cervical Cancer FIGO 2018", "Stage IIA1 Cervical Cancer FIGO 2018", "Stage IIA2 Cervical Cancer FIGO 2018", "Stage IIB Cervical Cancer FIGO 2018", "Stage III Cervical Cancer FIGO 2018", "Stage IIIA Cervical Cancer FIGO 2018", "Stage IIIB Cervical Cancer FIGO 2018", "Stage IIIC Cervical Cancer FIGO 2018", "Stage IIIC1 Cervical Cancer FIGO 2018", "Stage IIIC2 Cervical Cancer FIGO 2018", "Stage IV Cervical Cancer FIGO 2018", "Stage IVA Cervical Cancer FIGO 2018", "Stage IVB Cervical Cancer FIGO 2018" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2020-11-17", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Rochester, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04574635" }, { "nct_id": "NCT00601913", "title": "Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "protein analysis", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "liquid chromatography", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 24, "start_date": "2008-03", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601913" }, { "nct_id": "NCT07513389", "title": "Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma", "Human Papilloma Virus (HPV)", "Oropharyngeal Squamous Cell Carcinoma (OPSCC)" ], "interventions": [ { "name": "Active Surveillance With ctHPVDNA (NavDx®)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-08-12", "completion_date": "2034-07-01", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-16T19:07:46.645Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07513389" } ] }